sun pharmaceuticals
Jump to
38 Results Found
  • Quant Pick - Sun Pharmaceuticals: ICICI Direct Mar 05, 2021 01:39 PM IST

    Quant Pick - Sun Pharmaceuticals: ICICI Direct

    According to ICICI Direct, Buy Sun Pharmaceuticals in range of Rs 625-635 Target: Rs 738 Stop Loss: Rs 570 Time frame: Three months.

  • Buy Sun Pharmaceuticals; target of Rs 660: Dolat Capital Sep 21, 2020 02:38 PM IST

    Buy Sun Pharmaceuticals; target of Rs 660: Dolat Capital

    Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 660 in its research report dated September 21, 2020.

  • Buy Sun Pharmaceuticals; target of Rs 571: Dolat Capital Aug 09, 2020 09:14 PM IST

    Buy Sun Pharmaceuticals; target of Rs 571: Dolat Capital

    Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 571 in its research report dated August 01, 2020.

  • Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital Jun 15, 2020 12:40 PM IST

    Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital

    Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 530 in its research report dated June 11, 2020.

  • Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital May 28, 2020 03:01 PM IST

    Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital

    Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 530 in its research report dated May 27, 2020.

  • Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct Feb 18, 2019 04:01 PM IST

    Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct

    ICICI Direct recommended hold rating on Sun Pharmaceuticals with a target price of Rs 460 in its research report dated February 13, 2019.

  • Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct Dec 05, 2018 03:57 PM IST

    Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct

    ICICI Direct recommended hold rating on Sun Pharmaceuticals with a target price of Rs 460 in its research report dated December 04, 2018.

  • Buy Sun Pharmaceuticals; target of Rs 690: ICICI Direct Aug 20, 2018 04:48 PM IST

    Buy Sun Pharmaceuticals; target of Rs 690: ICICI Direct

    ICICI Direct is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 690 in its research report dated August 16, 2018.

  • Sun Pharma recalls over 5.2k units of testosterone cypionate injections from US Aug 05, 2018 10:05 AM IST

    Sun Pharma recalls over 5.2k units of testosterone cypionate injections from US

    The injections are used for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.

  • Sun Pharmaceuticals Q1 PAT seen up 68.7% YoY to Rs. 886.9 cr: Kotak Jul 18, 2018 03:33 PM IST

    Sun Pharmaceuticals Q1 PAT seen up 68.7% YoY to Rs. 886.9 cr: Kotak

    Net Sales are expected to increase by 14.3 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 7,096.3 crore, according to Kotak.

  • Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss Jun 05, 2018 11:26 AM IST

    Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss

    Edelweiss recommended hold rating on Sun Pharmaceuticals with a target price of Rs 480 in its research report dated May 25, 2018.

  • Hold Sun Pharmaceuticals; target of Rs 510: ICICI Direct Jun 04, 2018 01:48 PM IST

    Hold Sun Pharmaceuticals; target of Rs 510: ICICI Direct

    ICICI Direct is recommended hold rating on Sun Pharmaceuticals with a target price of Rs 510 in its research report dated May 28, 2018.

  • Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss Apr 05, 2018 05:03 PM IST

    Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss

    Edelweiss recommended hold rating on Sun Pharmaceuticals with a target price of Rs 480 in its research report dated April 05, 2018.

  • Sun Pharmaceuticals Q2 PAT may dip 62.3% YoY to Rs. 848.7 cr: Kotak Oct 13, 2017 06:20 PM IST

    Sun Pharmaceuticals Q2 PAT may dip 62.3% YoY to Rs. 848.7 cr: Kotak

    Net Sales are expected to decrease by 15.2 percent Y-o-Y (up 12.8 percent Q-o-Q) to Rs. 7006.1 crore, according to Kotak.

  • Analysts consensus is bearish on pharma stocks – should one buy? Aug 14, 2017 07:41 PM IST

    Analysts consensus is bearish on pharma stocks – should one buy?

    All generic pharmaceutical companies across the world and those involved in the distribution of generic drugs in the USA have seen their market value eroding sharply.

  • Hold Sun Pharmaceuticals; target of Rs 549: ICICI Direct May 29, 2017 05:19 PM IST

    Hold Sun Pharmaceuticals; target of Rs 549: ICICI Direct

    ICICI Direct recommended hold rating on Sun Pharmaceuticals with a target price of Rs 549 in its research report dated May 29, 2017.

  • Buy Sun Pharmaceuticals; target of Rs 680: Edelweiss May 29, 2017 03:42 PM IST

    Buy Sun Pharmaceuticals; target of Rs 680: Edelweiss

    Edelweiss is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 680 in its research report dated May 26, 2017.

  • Sun Pharma soars 6% on US FDA’s plan to lift import alert at Mohali Mar 14, 2017 02:07 PM IST

    Sun Pharma soars 6% on US FDA’s plan to lift import alert at Mohali

    The company informed the exchanges that the US Food and Drug Administration was planning to remove the firm from Official Action Initiated (OIA) status.

  • Sun Pharma in race to acquire InSite Vision? Sep 15, 2015 05:30 PM IST

    Sun Pharma in race to acquire InSite Vision?

    The company, however, did not name the suitor but reports suggested it was Sun Pharmaceuticals. Earlier in August, InSite Vision announced a definite agreement with drug firm QLT. InSite has notified QLT of the InSite Board of Directors' determination and will engage in discussions with the Bidder, it added.

  • Nine blue-chip cos add Rs 1,14,806 cr in m-cap Feb 23, 2014 11:27 AM IST

    Nine blue-chip cos add Rs 1,14,806 cr in m-cap

    As the benchmark sensitive index Sensex added over 300 points last week, nine of the top 10 most valued companies saw a combined addition of Rs 1,14,806 crore to their market capitalisation over the past week.

  • SP Tulsian positive on Lupin, may test Rs 910 Dec 03, 2013 11:53 AM IST

    SP Tulsian positive on Lupin, may test Rs 910

    SP Tulsian of sptulsian.com is positive on Lupin and Sun Pharmaceuticals.

  • Buy Sun Pharma, Cipla: Gopi Suvanam Nov 14, 2013 11:32 AM IST

    Buy Sun Pharma, Cipla: Gopi Suvanam

    According to Gopi Suvanam, Founder of InvestWorks, one may buy Cipla and Sun Pharmaceutical Industries in the pharma space.

  • Sun Pharma posts Rs 1276 cr loss in Q1 on Pfizer settlement Aug 09, 2013 04:52 PM IST

    Sun Pharma posts Rs 1276 cr loss in Q1 on Pfizer settlement

    Sun Pharmaceutical Industries today reported a consolidated net loss of Rs 1,276.1 crore in April-June as the company wrote-off Rs 2,517 crore on settlement of patent litigation with US-based Pfizer Inc.

  • LIC buys Rs 8,700cr shares in 17 Sensex cos in June quarter Jul 28, 2013 12:42 PM IST

    LIC buys Rs 8,700cr shares in 17 Sensex cos in June quarter

    State-run insurance giant LIC has increased its exposure in 17 blue-chip firms, with purchase of shares worth an estimated Rs 8,700 crore in the quarter ended June 30, 2013.

  • Lupin, Wipro, Idea to get astrological support: Gupta Jul 15, 2013 11:32 AM IST

    Lupin, Wipro, Idea to get astrological support: Gupta

    Technology stocks like Wipro, Tech Mahindra, HCL Technologies, Thinksoft Global Services, KPIT Cummins Infosystems and Tata Consultancy Services will get astrological support, says Satish Gupta of astrostocktips.in.

Sections